Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Acute-onset severe gastrointestinal tract hemorrhage in a postoperative patient taking rivaroxaban after total hip arthroplasty: a case report.

Boland M, Murphy M, Murphy M, McDermott E.

J Med Case Rep. 2012 May 14;6:129. doi: 10.1186/1752-1947-6-129.

2.

Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.

Beyer-Westendorf J, Lützner J, Donath L, Tittl L, Knoth H, Radke OC, Kuhlisch E, Stange T, Hartmann A, Günther KP, Weiss N, Werth S.

Thromb Haemost. 2013 Jan;109(1):154-63. doi: 10.1160/TH12-07-0510. Epub 2012 Nov 29.

PMID:
23197272
3.

Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.

Sindali K, Rose B, Soueid H, Jeer P, Saran D, Shrivastava R.

Eur J Orthop Surg Traumatol. 2013 May;23(4):481-6. doi: 10.1007/s00590-012-0987-y. Epub 2012 Apr 17.

PMID:
23412293
4.

Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.

[No authors listed]

Prescrire Int. 2009 Aug;18(102):151-3.

PMID:
19743567
5.

Discovery of Intra-Abdominal Hemorrhage during Hernioplasty in a Patient Taking Rivaroxaban.

Chow H, Ng MK.

Case Rep Surg. 2015;2015:345716. doi: 10.1155/2015/345716. Epub 2015 Apr 12.

6.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

7.

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P; ODIXa-HIP Study Investigators.

Circulation. 2006 Nov 28;114(22):2374-81. Epub 2006 Nov 20.

8.

Fatal gastrointestinal hemorrhage after a single dose of dabigatran.

Kernan L, Ito S, Shirazi F, Boesen K.

Clin Toxicol (Phila). 2012 Aug;50(7):571-3. doi: 10.3109/15563650.2012.705290. Epub 2012 Jul 17.

PMID:
22800505
9.
10.

A case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patient.

Yates J, Choudhry M, Keys G.

J Clin Pharm Ther. 2013 Apr;38(2):159-61. doi: 10.1111/jcpt.12013. Epub 2012 Nov 20.

PMID:
23167549
11.

Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.

Huisman MV, Quinlan DJ, Dahl OE, Schulman S.

Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):652-60. doi: 10.1161/CIRCOUTCOMES.110.957712. Epub 2010 Oct 5.

12.

Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.

Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kälebo P, Kwong LM, Misselwitz F, Turpie AG.

Clin Pharmacokinet. 2008;47(3):203-16.

PMID:
18307374
13.
14.

Extracorporeal photophoresis: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1.

15.

Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.

[No authors listed]

Prescrire Int. 2013 Jun;22(139):155-9. Review.

PMID:
23866358
16.

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.

Turpie AG, Schmidt AC, Kreutz R, Lassen MR, Jamal W, Mantovani L, Haas S.

Vasc Health Risk Manag. 2012;8:363-70. doi: 10.2147/VHRM.S30064. Epub 2012 Jun 1.

17.

[Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis].

Koscielny J, Beyer-Westendorf J, von Heymann C, Braun J, Klamroth R, Lindhoff-Last E, Tiede A, Spannagl M.

Hamostaseologie. 2012;32(4):287-93. doi: 10.5482/ha-2012030001. German.

PMID:
23114797
18.

Rivaroxaban: an oral factor Xa inhibitor.

Thomas TF, Ganetsky V, Spinler SA.

Clin Ther. 2013 Jan;35(1):4-27. doi: 10.1016/j.clinthera.2012.12.005. Review.

PMID:
23328267
19.

Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

Duggan ST.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):57-72. doi: 10.2165/11208470-000000000-00000. Review.

PMID:
22272729
20.

Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study.

Mills RM, Berkowitz RD, Damaraju CV, Jennings LK, Wildgoose P.

Thromb Res. 2012 Nov;130(5):709-15. doi: 10.1016/j.thromres.2012.07.014. Epub 2012 Aug 2.

PMID:
22857800
Items per page

Supplemental Content

Write to the Help Desk